The prognostic value of serum IFN-γ, MBL and sFas expression levels in patients with multiple myeloma

doi:10.11958/20241655

Abstract

Abstract:

Objective To investigate the prognostic value of serum interferon-γ (IFN-γ), mannose-binding lectin (MBL) and soluble Fas (sFas) expression levels in patients with multiple myeloma (MM). Methods A total of 150 MM patients diagnosed in our hospital were included in this study and used as the research subjects. According to ISS staging, patients were separated into the stage Ⅰ group (46 cases), the stage Ⅱ group (54 cases) and the stage Ⅲ group (50 cases). According to the survival status of MM patients, they were assigned into the survival group (n=98) and the death group (n=52). Enzyme linked immunosorbent assay (ELISA) was applied to detect expression levels of serum IFN-γ, MBL and sFas. The influencing factors of prognostic mortality in MM patients were analyzed by Cox proportional hazard regression model. The receiver operating curve (ROC) was plotted to analyze the diagnostic value of serum IFN-γ, MBL and sFas expression levels in the prognostic mortality of MM patients. Results With the improvement of ISS stage, the serum Ca level of patients increased significantly (P<0.05). With the improvement of ISS staging, the expression level of serum IFN-γ was greatly decreased, while the levels of serum MBL and sFas were significantly increased (P<0.05). The serum IFN-γ level was significantly lower in the death group than that of the survival group, while the serum MBL and sFas levels were significantly higher (P<0.05). The proportion of ISS Ⅲ stage and the level of serum Ca were significantly higher in the death group than those in the survival group (P<0.05). Elevated serum levels of MBL, sFas and Ca and ISS stage Ⅲ were risk factors for death within three years in patients with MM, and elevated serum IFN-γ level was protective factor for death within three years in patients with MM (P<0.05). The AUC of prognostic mortality in patients with combined serum IFN-γ, MBL and sFas in the diagnosis of MM was 0.977, which was better than that of patients diagnosed alone (Z=3.481, 3.952 and 3.832, P<0.05). Conclusion The decreased serum IFN-γ expression and the increased MBL and sFas levels are related to the three-year prognosis of MM patients, and the combination of the three has predictive value for death of MM patients, and which can be used as a biomarker for the prognosis evaluation of MM patients.

Key words: multiple myeloma, mannose-binding lectin, prognosis, interferon-gamma, soluble Fas

CLC Number:

R733.3

Figures/Tables 7

References 25

[1]	RAJKUMAR S V. Multiple myeloma:2024 update on diagnosis,risk-stratification,and management[J]. Am J Hematol,2024, 99(9):1802-1824. doi:10.1002/ajh.27422.
[2]	SHAH N, CHARI A, SCOTT E, et al. B-cell maturation antigen (BCMA) in multiple myeloma:rationale for targeting and current therapeutic approaches[J]. Leukemia, 2020, 34(4):985-1005. doi:10.1038/s41375-020-0734-z.
[3]	COWAN A J, GREEN D J, KWOK M, et al. Diagnosis and management of multiple myeloma:a review[J]. JAMA, 2022, 327(5):464-477. doi:10.1001/jama.2022.0003.
[4]	YU R, ZHU B, CHEN D. Type I interferon-mediated tumor immunity and its role in immunotherapy[J]. Cell Mol Life Sci, 2022, 79(3):191. doi:10.1007/s00018-022-04219-z.
[5]	曾雪娇, 谢仁古丽·阿力木, 张瑞, 等. 慢性淋巴细胞白血病患者血清IFN-γ、IL-17与IL-6水平变化及其相关性分析[J]. 山东医药, 2023, 63(14):86-88.
	ZENG X J, XIE REN GU LI·A L M, ZHANG R, et al. Changes in serum IFN-γ,IL-17 and IL-6 levels in patients with chronic lymphocytic leukemia and their correlations[J]. Shandong Medicine, 2023, 63(14):86-88. doi:10.3969/j.issn.1002-266X.2023.14.021.
[6]	VAN DER ZANDE H, NITSCHE D, SCHLAUTMANN L, et al. The mannose receptor:from endocytic receptor and biomarker to regulator of (Meta)inflammation[J]. Front Immunol, 2021, 12:765034. doi:10.3389/fimmu.2021.765034.
[7]	韦岩, 李芳, 马壮壮, 等. 成人急性白血病血清MBL、MASP1和MASP2检测及其临床价值[J]. 湖南师范大学学报(医学版), 2023, 20(1):44-47.
	WEI Y, LI F, MA Z Z, et al. Serum MBL,MASP1 and MASP2 in adults with acute leukemia and their clinical value[J]. Journal of Hunan Normal University(Medical Science), 2023, 20(1):44-47. doi:10.3969/j.issn.1673-016X.2023.01.008.
[8]	HASAN S, ALSHAIKH B, YUSUF K. Serum levels of soluble Fas and Fas ligand in pregnant women who smoke[J]. Am J Reprod Immunol, 2021, 85(6):e13382. doi:10.1111/aji.13382.
[9]	雷小茹, 戴进前, 任婧婧, 等. 血清sFas、IL-17对急性淋巴细胞白血病化疗效果的预测价值[J]. 检验医学与临床, 2023, 20(14):2023-2027.
	LEI X R, DAI J Q, REN J J, et al. Predictive value of serum sFas and IL-17 in chemotherapy effect of acute lymphoblastic leukemia[J]. Laboratory Medicine & Clinical, 2023, 20(14):2023-2027. doi:10.3969/j.issn.1672-9455.2023.14.008.
[10]	中国医师协会血液科医师分会,中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志, 2022, 61(5):480-487.
	Hematology Branch of Chinese Medical Doctor Association,Hematology Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of multiple myeloma in China(revised in 2022)[J]. Chinese Journal of Internal Medicine, 2022, 61(5):480-487. doi:10.3760/cma.j.cn112138-20220309-00165.
[11]	SZUDY-SZCZYREK A, MLAK R, MIELNIK M, et al. Circulating serum miRNA-8074 as a novel prognostic biomarker for multiple myeloma[J]. Cells, 2022, 11(4):752. doi:10.3390/cells11040752.
[12]	LUDWIG H, NOVIS DURIE S, MECKL A, et al. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality,economic resources,and patient empowerment[J]. Oncologist, 2020, 25(9):e1406-e1413. doi:10.1634/theoncologist.2020-0141.
[13]	BRAUNLIN M, BELANI R, BUCHANAN J, et al. Trends in the multiple myeloma treatment landscape and survival:a U.S. analysis using 2011-2019 oncology clinic electronic health record data[J]. Leuk Lymphoma, 2021, 62(2):377-386. doi:10.1080/10428194.2020.1827253.
[14]	MATTEUCCI F, PAGANELLI G, MARTINELLI G, et al. PET/CT in multiple myeloma:beyond FDG[J]. Front Oncol, 2020, 10:622501. doi:10.3389/fonc.2020.622501.
[15]	ALSPACH E, LUSSIER D M, SCHREIBER R D. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity[J]. Cold Spring Harb Perspect Biol, 2019, 11(3):a028480. doi:10.1101/cshperspect.a028480.
[16]	MARTINS L, MORITA A A, BROTO G E, et al. Interferon-gamma in mobilized stem cells:A possible prognostic marker in early post-transplant management in multiple myeloma[J]. Cytokine, 2018, 108:127-135. doi:10.1016/j.cyto.2018.03.006.
[17]	CHENG Y, SUN F, ALAPAT D V, et al. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma[J]. Cell Rep Med, 2023, 4(10):101214. doi:10.1016/j.xcrm.2023.101214.
[18]	CHEN Y, SHAO X, YANG H, et al. Interferon gamma regulates a complex pro-survival signal network in chronic lymphocytic leukemia[J]. Eur J Haematol, 2023, 110(4):435-443. doi:10.1111/ejh.13921.
[19]	KASHYAP S S, KAUR S, DEVGAN R K, et al. Impact of 5' near gene variants of mannose binding lectin (MBL2) on breast cancer risk[J]. Biochem Genet, 2024. doi:10.1007/s10528-024-10894-3. [Online ahead of print].
[20]	BĄK-ROMANISZYN L, ŚWIERZKO A S, SOKOłOWSKA A, et al. Mannose-binding lectin (MBL) in adult patients with inflammatory bowel disease[J]. Immunobiology, 2020, 225(1):151859. doi:10.1016/j.imbio.2019.10.008.
[21]	SOKOłOWSKA A, ŚWIERZKO A S, GAJEK G, et al. Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults[J]. Sci Rep, 2020, 10(1):10561. doi:10.1038/s41598-020-67516-2.
[22]	VILYS L, PECIULIENE I, JAKUBAUSKIENE E, et al. U2AF - Hypoxia-induced fas alternative splicing regulator[J]. Exp Cell Res, 2021, 399(1):112444. doi:10.1016/j.yexcr.2020.112444.
[23]	KUBO S, KATARIA R, YAO Y, et al. Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells[J]. Proc Natl Acad Sci U S A, 2022, 119(33):e2208522119. doi:10.1073/pnas.2208522119.
[24]	ADACHI Y, NOJIMA M, MORI M, et al. Serum soluble Fas levels and incidence of liver cancer in nested case-control study[J]. Cancer Epidemiol Biomarkers Prev, 2023, 32(2):260-265. doi:10.1158/1055-9965.EPI-22-0902.
[25]	何昊, 郑克春, 周友根, 等. 血清sICAM-1、VEGF、sFas水平在急性白血病中的变化及临床价值[J]. 国际检验医学杂志, 2024, 45(12):1487-1490.
	HE H, ZHENG K C, ZHOU Y G, et al. Changes of serum levels of sICAM-1,VEGF and sFas in acute leukemia and their clinical value[J]. International Journal of Laboratory Medicine, 2024, 45(12):1487-1490. doi:10.3969/j.issn.1673-4130.2024.12.015.

组别		n	男/女	年龄/岁		BMI/（kg/m²）		高血压史		糖尿病史
Ⅰ期组		46	24/22	68.57±6.93		22.97±2.31		28（60.9）		26（56.5）
Ⅱ期组		54	31/23	69.21±7.06		23.43±2.38		31（57.4）		29（53.7）
Ⅲ期组		50	29/21	69.62±7.14		23.67±2.42		30（60.0）		23（46.0）
χ²或F			0.398	0.269		1.071		0.137		1.161
组别	基础方案/含来那度胺方案				Hb/（g/L）		IgM/（g/L）		Ca/（mmol/L）
Ⅰ期组	27/19				80.05±8.07		54.03±5.45		2.42±0.25
Ⅱ期组	28/26				81.02±8.15		54.89±5.51		2.94±0.31^a
Ⅲ期组	28/22				82.03±8.29		55.47±5.59		3.58±0.37^ab
χ²或F	0.484				0.704		0.823		163.373^＊＊

组别		n	男/女	年龄/岁		BMI/（kg/m²）		高血压史		糖尿病史
Ⅰ期组		46	24/22	68.57±6.93		22.97±2.31		28（60.9）		26（56.5）
Ⅱ期组		54	31/23	69.21±7.06		23.43±2.38		31（57.4）		29（53.7）
Ⅲ期组		50	29/21	69.62±7.14		23.67±2.42		30（60.0）		23（46.0）
χ²或F			0.398	0.269		1.071		0.137		1.161
组别	基础方案/含来那度胺方案				Hb/（g/L）		IgM/（g/L）		Ca/（mmol/L）
Ⅰ期组	27/19				80.05±8.07		54.03±5.45		2.42±0.25
Ⅱ期组	28/26				81.02±8.15		54.89±5.51		2.94±0.31^a
Ⅲ期组	28/22				82.03±8.29		55.47±5.59		3.58±0.37^ab
χ²或F	0.484				0.704		0.823		163.373^＊＊

组别	n	IFN-γ/（ng/L）	MBL/（mg/L）	sFas/（mg/L）
Ⅰ期组	46	32.85±3.31	14.03±1.42	6.51±0.68
Ⅱ期组	54	29.61±3.03^a	16.35±1.72^a	8.19±0.82^a
Ⅲ期组	50	26.94±2.72^ab	18.64±2.09^ab	9.64±1.07^ab
F		45.877^＊＊	81.115^＊＊	153.343^＊＊

组别	n	IFN-γ/（ng/L）	MBL/（mg/L）	sFas/（mg/L）
Ⅰ期组	46	32.85±3.31	14.03±1.42	6.51±0.68
Ⅱ期组	54	29.61±3.03^a	16.35±1.72^a	8.19±0.82^a
Ⅲ期组	50	26.94±2.72^ab	18.64±2.09^ab	9.64±1.07^ab
F		45.877^＊＊	81.115^＊＊	153.343^＊＊

组别	n	IFN-γ/（ng/L）	MBL/（mg/L）	sFas/（mg/L）
生存组	98	31.11±3.35	15.61±1.65	7.77±0.82
死亡组	52	27.08±2.76	17.89±1.96	8.89±0.97
t		7.435^＊＊	7.869^＊＊	7.464^＊＊